Cibc World Market Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 84.0% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 120,866 shares of the medical research company's stock after purchasing an additional 55,181 shares during the period. Cibc World Market Inc.'s holdings in Amgen were worth $50,946,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Wellington Altus USA Inc. grew its stake in shares of Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company's stock worth $28,000 after purchasing an additional 34 shares during the period. Quest 10 Wealth Builders Inc. grew its position in Amgen by 220.0% during the third quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company's stock valued at $34,000 after buying an additional 55 shares during the period. Nvwm LLC grew its position in Amgen by 412.5% during the third quarter. Nvwm LLC now owns 82 shares of the medical research company's stock valued at $35,000 after buying an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA purchased a new position in Amgen in the second quarter valued at $36,000. Finally, PFS Partners LLC increased its holdings in Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company's stock valued at $36,000 after buying an additional 42 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Stock Down 0.9%
AMGN opened at $457.93 on Wednesday. The company has a 50-day moving average price of $427.10 and a 200 day moving average price of $382.34. Amgen Inc. has a twelve month low of $312.39 and a twelve month high of $483.99. The company has a market cap of $247.70 billion, a PE ratio of 26.56, a price-to-earnings-growth ratio of 3.22 and a beta of 0.43. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60.
Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The business's quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $5.64 earnings per share. Sell-side analysts expect that Amgen Inc. will post 23.37 earnings per share for the current fiscal year.
Amgen Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen's dividend payout ratio is currently 58.47%.
Trending Headlines about Amgen
Investors following AMGN have been watching these headlines:
- Positive Sentiment: Amgen has raised its 2026 outlook twice, with newer products helping offset pressure on Prolia and XGEVA. A broader biotech-industry report also cites strong 2026 results and raised outlooks among leading companies, including Amgen. Amgen outlook and product pressures Biotechnology market outlook
- Positive Sentiment: Amgen’s obesity-treatment candidate is described as a potential rival in a market led by Novo Nordisk, offering a possible future growth opportunity. Novo Nordisk versus Amgen
- Neutral Sentiment: Amgen published detailed Phase 3 results for dazodalibep in Sjögren’s disease, adding clinical information for investors; the article excerpt does not specify the results’ implications. Dazodalibep Phase 3 data
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on AMGN shares. Citigroup increased their target price on shares of Amgen from $405.00 to $465.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 4th. Argus raised their target price on Amgen from $460.00 to $515.00 and gave the company a "buy" rating in a research report on Thursday, November 12th. Robert W. Baird lifted their price target on Amgen from $215.00 to $230.00 and gave the company an "underperform" rating in a research note on Wednesday, August 5th. Guggenheim upped their price target on Amgen from $378.00 to $435.00 and gave the stock a "neutral" rating in a report on Thursday, November 5th. Finally, Royal Bank Of Canada increased their price target on Amgen from $430.00 to $470.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eighteen have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $425.69.
Get Our Latest Stock Analysis on AMGN
About Amgen
(
Free Report)
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company's medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.